Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Pandey, Aseem ^a,b   Singh, Neetu ^a,b   Vemula, Sai V ^a,b   Couëtil, Laurent ^a   Katz, Jacqueline M ^c   Donis, Ruben ^c   Sambhara, Suryaprakash ^c   Mittal, Suresh K ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS NUCLEOPROTEIN; CORE PROTEIN; EPITOPE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN; VIRUS ANTIBODY;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; WILD TYPE; ADENOVIRUS; ANIMAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENE VECTOR; GENETIC REASSORTMENT; GENETICS; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; IMMUNITY; IMMUNOLOGY; INFLUENZA; METABOLISM; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; MUS; ORTHOMYXOVIRIDAE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MICE; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; RNA-BINDING PROTEINS; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 84858162568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033428     Document Type: Article

References (41)

1. Bangari DS, Mittal SK, (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24: 849-862.
2. Vemula SV, Mittal SK, (2010) Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther 10: 1469-1487.
3. Zhu J, Huang X, Yang Y, (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virol 81: 3170-3180.
4. Sharma A, Bangari DS, Tandon M, HogenEsch H, Mittal SK, (2010) Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res 153: 134-142.
5. Fooks AR, Schadeck E, Liebert UG, Dowsett AB, Rima BK, et al. (1995) High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210: 456-465.
6. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, et al. (2003) Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362: 1895-1896.
7. Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, et al. (1989) Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 86: 6763-6767.
8. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
9. Barouch DH, Nabel GJ, (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16: 149-156.
10. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
11. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu XH, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
12. Hoelscher MA, Jayashankar L, Garg S, Veguilla V, Lu X, et al. (2007) New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 82: 665-671.
13. Bangari DS, Shukla S, Mittal SK, (2005) Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 327: 960-966.
14. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18: 1213-1216.
15. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, et al. (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11: 351-357.
16. Mittal SK, McDermott MR, Johnson DC, Prevec L, Graham FL, (1993) Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 28: 67-90.
17. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM, (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3: 137-144.
18. Singh N, Pandey A, Jayashankar L, Mittal SK, (2008) Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 16: 965-971.
19. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
20. Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U, et al. (1999) A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10: 2667-2672.
21. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.
22. Bender BS, Small PA Jr, (1992) Influenza: pathogenesis and host defense. Semin Respir Infect 7: 38-45.
23. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC, (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
24. Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, et al. (2008) A broadly-protective vaccine against globally dispersed clade 1 and clade 2 H5N1 viruses. J Inf Dis 197: 1185-1188.
25. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, et al. (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-1036.
26. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, et al. (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77: 10078-10087.
27. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
28. Vos A, Neubert A, Pommerening E, Muller T, Dohner L, et al. (2001) Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J Gen Virol 82: 2191-2197.
29. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, et al. (2010) Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28: 1932-1941.
30. Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH, (2010) Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol 84: 5986-5996.
31. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649.
32. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548-.
33. Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S, (2006) Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8: 92-104.
34. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, et al. (2003) Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77: 10780-10789.
35. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
36. van Olphen AL, Mittal SK, (2002) Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J Virol 76: 5882-5892.
37. Bangari DS, Mittal SK, (2004) Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 105: 127-136.
38. van Olphen AL, Tikoo SK, Mittal SK, (2002) Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 295: 108-118.
39. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796-801.
40. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC, (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-95.
41. Sambhara S, Switzer I, Kurichh A, Miranda R, Urbanczyk L, et al. (1998) Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice. Cell Immunol 187: 13-18.